Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 163 results for thrombosis

  1. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

    Medtech innovation briefing
    Published
    18 January 2017

  2. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

    Medtech innovation briefing
    Published
    11 August 2020

  3. Airglove air warming system for venous access (MIB151)

    NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .

    Medtech innovation briefing
    Published
    6 July 2018

  4. Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA275)

    Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

    Technology appraisal guidance
    Last updated
    2 July 2021
    View recommendations

    Sections for TA275

  5. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

    Evidence summary
    Published
    24 May 2016

  6. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA304

  7. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)

    This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.

    Withdrawn guideline

  8. Liposuction for chronic lipoedema (HTG618)

    Evidence-based recommendations on liposuction for chronic lipoedema in adults. This involves using suction to remove abnormal fat.

    HealthTech guidance
    Published
    29 March 2022
    View recommendations

    Sections for HTG618

  9. Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

    Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.

    Technology appraisal guidance
    Published
    23 June 2021
    View recommendations

    Sections for TA710

  10. Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)

    Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Last updated
    3 July 2024
    View recommendations

    Sections for TA688

  11. Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)

    Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.

    HealthTech guidance
    Published
    23 May 2007
    View recommendations

    Sections for HTG141

  12. Radiofrequency ablation of varicose veins (HTG2)

    Evidence-based recommendations on radiofrequency ablation of varicose veins. This involves using radiofrequency energy to heat the wall of the vein so that it collapses.

    HealthTech guidance
    Published
    24 September 2003
    View recommendations

    Sections for HTG2

  13. Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (HTG325)

    Evidence-based recommendations on percutaneous closure of the patent foramen ovale for the prevention of cerebral embolic stroke. This involves placing a small device into the heart to close the hole.

    HealthTech guidance
    Published
    18 December 2013
    View recommendations

    Sections for HTG325

  14. HemaClear for bloodless surgical field during limb surgery (MIB187)

    NICE has developed a medtech innovation briefing (MIB) on HemaClear for bloodless surgical field during limb surgery .

    Medtech innovation briefing
    Published
    15 July 2019

  15. Current evidence on the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but infrequent complications. For distal DVT that does not extend into the common femoral vein the evidence on efficacy is inconclusive, therefore this procedure should only be used in the context of  research .

    the safety of percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg shows there are well-recognised but...

    Research recommendation
    Published
    15 November 2019